Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
NEWARK, Calif., Jan. 27, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will hold an Analyst and Investor Day in New York City on Wednesday, March 23, 2016 from 9:00 a.m. ET – 11:30 a.m. ET (6:00 a.m. PT – 8:30 a.m. PT). Depomed’s President and Chief Executive Officer Jim Schoeneck and members of the company's management team will be joined by Joseph V. Pergolizzi, Jr., MD, an Adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine in Baltimore, Maryland and an internationally recognized leader in the area of pain medicine and management. The event will provide a business overview as well as a review of the marketed and development-stage product pipeline.
Space is limited and attendance is by invitation only. The presentations, as well as the question and answer session, will be webcast and will be accessible via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days. Additional event details will be available closer to the event date.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
